



Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
Quarterly Key Pharmacy Benefit Metrics
Data Reviewed Through: 3rd Quarter 2018

Quarterly Key Pharmacy Benefit Metrics


Executive Summary

- 3Q cost analysis:
 - All 3 entities experienced an increase in cost in the month of August, driven by increased specialty claims
 - Overall specialty costs are up 28% in the 3Q compared to the 2Q and 9.45% from 3Q 2017 and we expect this trend to continue
 - Savings could be realized by moving specialty retail to mail (analysis provided)
- Mail service plan cost is less than 2% of overall plan cost and claims utilization remains under 1% (measured by mail service channel specifically)
 - Savings could be recognized by moving retail 90 to mail service (analysis provided)
- Generic dispensing rates continue to increase in all channels
 - This is a positive trend as a result of the SJVIA clinical programs that focus on drugs with lower prices and high value, which helps both the plan and the member save on their pharmacy costs without sacrificing quality or care

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Gross Cost	\$4,737,910	\$4,808,924	\$4,939,413	\$4,899,021	\$4,990,468	\$4,929,823	\$5,298,177
Plan Cost	\$4,376,249	\$4,472,101	\$4,593,429	\$4,523,675	\$4,595,382	\$4,548,023	\$4,923,348
Member Cost	\$361,660	\$336,823	\$345,985	\$375,346	\$395,086	\$381,800	\$374,829




- This report details the total member and plan costs, by quarter, for the most recent 7 quarter period
- Gross cost = plan cost + member cost
- Overall gross cost increased due to higher utilization and an increase in high cost medications (specialty)

Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	\$1,510,923	\$1,516,602	\$1,534,294	\$1,496,887	\$1,408,220	\$1,416,756	\$1,382,438
Retail Generic	\$538,763	\$385,029	\$435,717	\$580,876	\$688,179	\$644,661	\$648,385
Retail 90 Brand	\$883,446	\$859,373	\$876,606	\$876,290	\$776,583	\$747,114	\$796,002
Retail 90 Generic	\$340,511	\$259,552	\$298,341	\$397,336	\$419,270	\$420,632	\$418,140
Mail Brand	\$79,808	\$75,303	\$53,762	\$52,183	\$50,613	\$50,585	\$47,329
Mail Generic	\$14,089	\$11,700	\$13,595	\$14,806	\$13,835	\$11,804	\$17,093
Specialty	\$1,008,709	\$1,364,541	\$1,381,113	\$1,105,297	\$1,238,682	\$1,256,471	\$1,613,960



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	4,590	4,430	4,406	4,425	4,225	3,875	3,951
Retail Generic	21,812	20,827	20,076	19,697	20,330	18,668	18,324
Retail 90 Brand	1,304	1,291	1,281	1,271	869	899	896
Retail 90 Generic	5,781	5,819	5,856	5,954	5,569	6,029	5,975
Mail Brand	64	60	47	47	53	47	47
Mail Generic	190	222	204	183	173	179	193
Specialty	255	290	301	291	361	358	429



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Specialty Plan Cost	\$1,008,709	\$1,364,541	\$1,381,113	\$1,105,297	\$1,238,682	\$1,256,471	\$1,613,960
Total Plan Cost	\$4,376,249	\$4,472,101	\$4,593,429	\$4,523,675	\$4,595,382	\$4,548,023	\$4,923,348
Specialty Plan Cost %	23.05%	30.51%	30.07%	24.43%	26.95%	27.63%	32.78%




- Specialty plan cost represents almost 33% of the SJVIA plan cost
- This represents a nearly 10% increase from Q1 2017 and steady increase quarter over quarter
- Specialty drugs are expected to account for half of total drug spend by 2020 even though only 1% to 2% of members use specialty drugs
- Specialty drug costs have increased 55% under the medical benefit since 2011 and double-digit annual specialty trend under the pharmacy benefit is the norm, not the exception

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail GDR	82.61%	82.46%	82.00%	81.66%	82.79%	82.81%	82.26%
Retail 90 GDR	81.59%	81.84%	82.05%	82.41%	86.50%	87.02%	86.96%
Mail GDR	74.80%	78.72%	81.27%	79.57%	76.55%	79.20%	80.42%





- Overall the generic dispensing rate continues to improve
- Retail 90 GDR has increased to 87%
- Formulary and plan design management have contributed to the improvement
- Excludes specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Plan Cost	\$3,273,644	\$3,020,556	\$3,144,959	\$3,351,389	\$3,292,253	\$3,229,163	\$3,244,966
Mail Plan Cost	\$93,897	\$87,004	\$67,357	\$66,989	\$64,448	\$62,389	\$64,422
Retail Plan Cost %	97.21%	97.20%	97.90%	98.04%	98.08%	98.10%	98.05%
Mail Plan Cost %	2.79%	2.80%	2.10%	1.96%	1.92%	1.90%	1.95%



- Mail service cost as a % of overall cost has steadily decreased
- Mail service claims are just .80% of all claims
- Excludes specialty

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: SJVIA

TOP DRUGS BY INGREDIENT COST

Based on Paid Date: 1/1/2018 - 9/30/2018

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	103	18	\$621,125.92	2,820	\$6,030.35	\$220.26
H.P. ACTHAR	*ENDOCRINE AND METABOLIC AGENTS - MISC.*	B	2	Y	13	1	\$527,842.25	221	\$40,603.25	\$2,388.43
LATUDA	*ANTIPSYCHOTICS/ANTIMANIC AGENTS*	B	2	N	183	41	\$324,202.66	6,630	\$1,771.60	\$48.90
ENBREL SURECLICK	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	59	11	\$302,785.05	1,652	\$5,131.95	\$183.28
TRULICITY	*ANTIDIABETICS*	B	2	N	308	77	\$297,620.93	11,692	\$966.30	\$25.46
VICTOZA	*ANTIDIABETICS*	B	2	N	219	47	\$223,975.43	9,275	\$1,022.72	\$24.15
JANUVIA	*ANTIDIABETICS*	B	2	N	311	86	\$219,537.05	15,600	\$705.91	\$14.07
CIALIS	*CARDIOVASCULAR AGENTS - MISC.*	B	2	N	323	111	\$201,370.53	15,513	\$623.44	\$12.98
ORKAMBI	*RESPIRATORY AGENTS - MISC.*	B	2	Y	9	1	\$196,557.12	252	\$21,839.68	\$779.99
LANTUS SOLOSTAR	*ANTIDIABETICS*	B	2	N	286	84	\$185,847.98	14,240	\$649.82	\$13.05
TECFIDERA	*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS*	B	2	Y	23	3	\$176,861.49	690	\$7,689.63	\$256.32
LYRICA	*ANTICONVULSANTS*	B	2	N	269	60	\$169,560.57	10,050	\$630.34	\$16.87
FARXIGA	*ANTIDIABETICS*	B	2	N	233	56	\$168,296.82	11,130	\$722.30	\$15.12
HUMALOG KWIKPEN	*ANTIDIABETICS*	B	2	N	142	46	\$163,855.16	6,196	\$1,153.91	\$26.45
HUMALOG	*ANTIDIABETICS*	B	2	N	125	35	\$161,671.86	5,498	\$1,293.37	\$29.41
SPRYCEL	*ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES*	B	2	Y	12	2	\$154,944.82	360	\$12,912.07	\$430.40
REVLIMID	*MISCELLANEOUS THERAPEUTIC CLASSES*	B	2	Y	9	1	\$132,872.46	252	\$14,763.61	\$527.27
INVOKANA	*ANTIDIABETICS*	B	2	N	163	44	\$129,285.27	8,500	\$793.16	\$15.21
ZYTIGA	*ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES*	B	2	Y	12	2	\$126,715.02	360	\$10,559.59	\$351.99
STELARA	*DERMATOLOGICALS*	B	2	Y	6	2	\$125,975.91	522	\$20,995.99	\$241.33
ADVAIR DISKUS	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	227	78	\$125,964.47	9,570	\$554.91	\$13.16
HARVONI	*ANTIVIRALS*	B	2	Y	4	2	\$125,496.00	112	\$31,374.00	\$1,120.50
NOVOLOG FLEXPEN	*ANTIDIABETICS*	B	2	N	117	37	\$118,401.83	5,664	\$1,011.98	\$20.90
NOXAFIL	*ANTIFUNGALS*	B	2	N	16	2	\$113,843.98	480	\$7,115.25	\$237.17
JARDIANCE	*ANTIDIABETICS*	B	2	N	127	52	\$110,289.53	7,290	\$868.42	\$15.13

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: SJVIA

TOP DRUGS BY CLAIM COUNT

Based on Paid Date: 1/1/2018 - 9/30/2018

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HYDROCODONE/ACETAMINOPHEN	*ANALGESICS - OPIOID*	G	1	N	2,212	880	\$84,982.02	42,373	\$38.42	\$2.01
LEVOTHYroxINE SODIUM	*THYROID AGENTS*	G	1	N	2,211	609	\$57,659.64	130,754	\$26.08	\$0.44
ATORVASTATIN CALCIUM	*ANTHYPERLIPIDEMICS*	G	1	N	2,195	730	\$71,572.41	138,471	\$32.61	\$0.52
LISINAPRIL	*ANTHYPERTENSIVES*	G	1	N	2,109	668	\$15,077.44	129,403	\$7.15	\$0.12
METFORMIN HCL	*ANTIDIABETICS*	G	1	N	1,561	508	\$27,669.44	86,413	\$17.73	\$0.32
OMEPRazole	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	1,249	490	\$25,352.94	68,256	\$20.30	\$0.37
GABAPENTIN	*ANTICONVULSANTS*	G	1	N	1,238	388	\$32,318.99	47,537	\$26.11	\$0.68
AMLODIPINE BESYLATE	*CALCIUM CHANNEL BLOCKERS*	G	1	N	1,237	382	\$7,804.94	73,825	\$6.31	\$0.11
AZITHROMYCIN	*MACROLIDES*	G	1	N	1,122	981	\$19,011.12	6,475	\$16.94	\$2.94
SERTRALINE HCL	*ANTIDEPRESSANTS*	G	1	N	1,085	326	\$13,875.20	52,229	\$12.79	\$0.27
AMOXICILLIN	*PENICILLINS*	G	1	N	1,008	880	\$7,812.35	8,844	\$7.75	\$0.88
ALPRAZOLAM	*ANTIAnXIETY AGENTS*	G	1	N	995	322	\$4,570.62	26,095	\$4.59	\$0.18
FLUTICASONE PROPIONATE	*NASAL AGENTS - SYSTEMIC AND TOPICAL*	G	1	N	976	629	\$21,482.20	38,445	\$22.01	\$0.56
MONTELUKAST SODIUM	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	G	1	N	926	324	\$24,485.19	42,895	\$26.44	\$0.57
LOSARTAN POTASSIUM	*ANTHYPERTENSIVES*	G	1	N	917	298	\$17,133.72	53,998	\$18.68	\$0.32
AMOXICILLIN/CLAVULANATE P	*PENICILLINS*	G	1	N	890	779	\$38,190.29	9,137	\$42.91	\$4.18
METOPROLOL SUCCINATE ER	*BETA BLOCKERS*	G	1	N	875	271	\$53,310.73	53,300	\$60.93	\$1.00
PREDNISONE	*CORTICOSTEROIDS*	G	1	N	781	548	\$5,173.96	11,922	\$6.62	\$0.43
BUPROPION HCL XL	*ANTIDEPRESSANTS*	G	1	N	773	227	\$72,241.83	36,925	\$93.46	\$1.96
HYDROCHLOROTHIAZIDE	*DIURETICS*	G	1	N	766	263	\$5,726.99	44,433	\$7.48	\$0.13
PROAIR HFA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	747	511	\$48,990.87	17,664	\$65.58	\$2.77
PANTOPRAZOLE SODIUM	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	731	244	\$13,654.52	39,250	\$18.68	\$0.35
IBU	*ANALGESICS - ANTI-INFLAMMATORY*	G	1	N	708	562	\$8,620.99	15,719	\$12.18	\$0.55
VENTOLIN HFA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	697	538	\$38,166.87	14,989	\$54.76	\$2.55
ESCITALOPRAM OXALATE	*ANTIDEPRESSANTS*	G	1	N	693	217	\$15,426.74	31,843	\$22.26	\$0.48

Quarterly Key Pharmacy Benefit Metrics

Specialty Drug Oversight

- The management of specialty drugs is complex, as are the conditions that specialty drugs treat. With recent advances in drug therapies, patients with complex conditions now have better options to manage their conditions. While plan sponsors like the SJVIA recognize the value of these medications to their members and want to provide best-in-class drug benefits, the cost management of these drugs requires utilization management and benefit design strategies.
- Strategies implemented for the SJVIA include:
 - Prior authorization/clinical review
 - Specialty pharmacy channel management
 - Ongoing formulary review for the most cost and clinically effective medications
 - Manufacturer assistance when available
- KPS is collaborating with EmpiRx on developing a clinical review report card

Quarterly Key Pharmacy Benefit Metrics

Rebates & Clinical Management Savings


- Rebates for the first two quarters:
 - Prescription drug rebates for the first quarter were \$381,625
 - We conservatively estimate second quarter at \$303,729 to come up with the \$685,354 six-month projection
 - Rebates are reported 180 days after the end of the applicable quarter
- Guaranteed clinical management savings over the first two quarters:
 - Clinical savings guarantee: \$1,850,000 - \$2,250,000 for Year 1
 - Estimated clinical savings as of June 30, 2018: \$2,078,376
- Final reconciliation is completed by EmpiRx clinicians 120 days post contract year
- Keenan performs a clinical savings financial audit and presents the final report to the SJVIA upon completion of the end of the plan year

Appendix

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Tulare)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Gross Cost	\$1,830,622	\$1,805,236	\$2,079,011	\$2,075,510	\$2,045,541	\$2,105,033	\$2,210,456
Plan Cost	\$1,681,806	\$1,664,669	\$1,929,998	\$1,914,890	\$1,877,531	\$1,939,021	\$2,044,745
Member Cost	\$148,817	\$140,566	\$149,013	\$160,619	\$168,010	\$166,012	\$165,710




This report details the total member and plan costs, by quarter, for the most recent 7 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Fresno)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Gross Cost	\$2,878,311	\$2,977,913	\$2,830,745	\$2,793,118	\$2,920,361	\$2,800,802	\$3,003,317
Plan Cost	\$2,668,854	\$2,784,721	\$2,636,776	\$2,581,065	\$2,696,115	\$2,587,785	\$2,796,816
Member Cost	\$209,457	\$193,192	\$193,969	\$212,052	\$224,246	\$213,016	\$206,502




This report details the total member and plan costs, by quarter, for the most recent 7 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Marysville)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Gross Cost	\$28,977	\$25,775	\$29,658	\$30,393	\$24,567	\$23,988	\$84,404
Plan Cost	\$25,590	\$22,711	\$26,655	\$27,719	\$21,736	\$21,216	\$81,787
Member Cost	\$3,387	\$3,064	\$3,003	\$2,674	\$2,831	\$2,771	\$2,618




This report details the total member and plan costs, by quarter, for the most recent 7 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Tulare)


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	\$594,629	\$591,250	\$603,917	\$585,904	\$544,469	\$558,061	\$560,157
Retail Generic	\$210,160	\$156,428	\$178,656	\$241,682	\$267,274	\$251,292	\$256,840
Retail 90 Brand	\$292,100	\$303,754	\$330,379	\$317,787	\$283,170	\$270,806	\$284,354
Retail 90 Generic	\$126,358	\$91,099	\$117,297	\$152,298	\$157,138	\$161,430	\$159,937
Mail Brand	\$66,377	\$48,190	\$36,595	\$33,811	\$27,587	\$35,568	\$34,599
Mail Generic	\$13,026	\$10,110	\$12,057	\$12,651	\$9,004	\$8,833	\$11,922
Specialty	\$379,156	\$463,839	\$651,097	\$570,758	\$588,889	\$653,031	\$736,936



Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Fresno)


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	\$900,166	\$910,260	\$912,901	\$894,531	\$860,792	\$854,458	\$818,790
Retail Generic	\$323,043	\$225,604	\$252,432	\$332,568	\$413,186	\$389,136	\$387,045
Retail 90 Brand	\$589,068	\$552,416	\$543,444	\$555,991	\$490,139	\$474,200	\$510,673
Retail 90 Generic	\$212,633	\$167,117	\$179,381	\$242,995	\$260,474	\$257,629	\$256,540
Mail Brand	\$13,431	\$27,114	\$17,167	\$18,372	\$23,026	\$15,017	\$12,730
Mail Generic	\$961	\$1,508	\$1,436	\$2,069	\$4,705	\$2,846	\$5,131
Specialty	\$629,553	\$900,703	\$730,015	\$534,540	\$643,792	\$594,500	\$805,907



Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Marysville)


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	\$16,128	\$15,093	\$17,476	\$16,452	\$2,960	\$4,237	\$3,491
Retail Generic	\$5,560	\$2,997	\$4,630	\$6,627	\$7,719	\$4,233	\$4,500
Retail 90 Brand	\$2,279	\$3,203	\$2,783	\$2,511	\$3,274	\$2,107	\$975
Retail 90 Generic	\$1,521	\$1,336	\$1,663	\$2,043	\$1,658	\$1,574	\$1,663
Mail Brand	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Mail Generic	\$102	\$83	\$102	\$86	\$125	\$125	\$40
Specialty	\$0	\$0	\$0	\$0	\$6,000	\$8,940	\$71,117



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Tulare)


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	1,693	1,661	1,705	1,755	1,568	1,496	1,562
Retail Generic	9,113	8,961	8,719	8,928	8,726	7,983	7,998
Retail 90 Brand	433	415	452	460	305	327	331
Retail 90 Generic	2,155	2,162	2,243	2,365	2,106	2,339	2,279
Mail Brand	48	41	33	35	30	30	33
Mail Generic	135	156	145	138	126	133	153
Specialty	98	99	120	114	134	149	169



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Fresno)


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	2,870	2,736	2,672	2,642	2,640	2,358	2,370
Retail Generic	12,493	11,693	11,181	10,613	11,447	10,540	10,196
Retail 90 Brand	865	867	821	805	557	567	562
Retail 90 Generic	3,589	3,612	3,563	3,552	3,425	3,657	3,665
Mail Brand	16	19	14	12	23	17	14
Mail Generic	52	63	56	42	44	43	38
Specialty	157	191	181	177	221	205	253



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Marysville)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Brand	27	33	29	28	17	21	19
Retail Generic	206	173	176	156	157	145	130
Retail 90 Brand	6	9	8	6	7	5	3
Retail 90 Generic	37	45	50	37	38	33	31
Mail Brand	0	0	0	0	0	0	0
Mail Generic	3	3	3	3	3	3	2
Specialty	0	0	0	0	6	4	7



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Tulare)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Specialty Plan Cost	\$379,156	\$463,839	\$651,097	\$570,758	\$588,889	\$653,031	\$736,936
Total Plan Cost	\$1,681,806	\$1,664,669	\$1,929,998	\$1,914,890	\$1,877,531	\$1,939,021	\$2,044,745
Specialty Plan Cost %	22.54%	27.86%	33.74%	29.81%	31.37%	33.68%	36.04%



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Fresno)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Specialty Plan Cost	\$629,553	\$900,703	\$730,015	\$534,540	\$643,792	\$594,500	\$805,907
Total Plan Cost	\$2,668,854	\$2,784,721	\$2,636,776	\$2,581,065	\$2,696,115	\$2,587,785	\$2,796,816
Specialty Plan Cost %	23.59%	32.34%	27.69%	20.71%	23.88%	22.97%	28.82%



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Marysville)


Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Specialty Plan Cost					\$6,000	\$8,940	\$71,117
Total Plan Cost	\$25,590	\$22,711	\$26,655	\$27,719	\$21,736	\$21,216	\$81,787
Specialty Plan Cost %	0.00%	0.00%	0.00%	0.00%	27.61%	42.14%	86.95%



Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Tulare)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail GDR	84.33%	84.36%	83.64%	83.57%	84.77%	84.22%	83.66%
Retail 90 GDR	83.27%	83.90%	83.23%	83.72%	87.35%	87.73%	87.32%
Mail GDR	73.77%	79.19%	81.46%	79.77%	80.77%	81.60%	82.26%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Fresno)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail GDR	81.32%	81.04%	80.71%	80.07%	81.26%	81.72%	81.14%
Retail 90 GDR	80.58%	80.64%	81.27%	81.52%	86.01%	86.58%	86.70%
Mail GDR	76.47%	76.83%	80.00%	77.78%	65.67%	71.67%	73.08%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Marysville)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail GDR	88.41%	83.98%	85.85%	84.78%	90.23%	87.35%	87.25%
Retail 90 GDR	86.05%	83.33%	86.21%	86.05%	84.44%	86.84%	91.18%
Mail GDR	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%





Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Tulare)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Plan Cost	\$1,223,247	\$1,142,532	\$1,230,248	\$1,297,671	\$1,252,051	\$1,241,589	\$1,261,289
Mail Plan Cost	\$79,403	\$58,299	\$48,653	\$46,462	\$36,592	\$44,402	\$46,521
Retail Plan Cost %	93.90%	95.15%	96.20%	96.54%	97.16%	96.55%	96.44%
Mail Plan Cost %	6.10%	4.85%	3.80%	3.46%	2.84%	3.45%	3.56%





Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Fresno)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Plan Cost	\$2,024,909	\$1,855,396	\$1,888,158	\$2,026,085	\$2,024,591	\$1,975,423	\$1,973,047
Mail Plan Cost	\$14,392	\$28,622	\$18,602	\$20,441	\$27,731	\$17,862	\$17,862
Retail Plan Cost %	99.29%	98.48%	99.02%	99.00%	98.65%	99.10%	99.10%
Mail Plan Cost %	0.71%	1.52%	0.98%	1.00%	1.35%	0.90%	0.90%





Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Marysville)

Category	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Retail Plan Cost	\$25,488	\$22,628	\$26,553	\$27,633	\$15,611	\$12,151	\$10,630
Mail Plan Cost	\$102	\$83	\$102	\$86	\$125	\$125	\$40
Retail Plan Cost %	99.60%	99.64%	99.62%	99.69%	99.21%	98.98%	99.63%
Mail Plan Cost %	0.40%	0.36%	0.38%	0.31%	0.79%	1.02%	0.37%



Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Tulare

TOP DRUGS BY INGREDIENT COST

County of Tulare

Based on Paid Date: 1/1/2018 - 9/30/2018

Client ID	Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
19027	H.P. ACTHAR	*ENDOCRINE AND METABOLIC AGENTS - MISC.*	B	2	Y	13	1	\$527,842.25	221	\$40,603.25	\$2,388.43
19027	HUMIRA PEN	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	51	7	\$308,399.70	1,364	\$6,047.05	\$226.10
19027	ORKAMBI	*RESPIRATORY AGENTS - MISC.*	B	2	Y	9	1	\$196,557.12	252	\$21,839.68	\$779.99
19027	TRULICITY	*ANTIDIABETICS*	B	2	N	135	32	\$131,202.88	5,138	\$971.87	\$25.54
19027	ZYTIGA	*ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES*	B	2	Y	12	2	\$126,715.02	360	\$10,559.59	\$351.99
19027	LYRICA	*ANTICONVULSANTS*	B	2	N	156	30	\$101,956.78	6,085	\$653.57	\$16.76
19027	TECFIDERA	*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.*	B	2	Y	13	2	\$99,965.19	390	\$7,689.63	\$256.32
19027	VICTOZA	*ANTIDIABETICS*	B	2	N	99	19	\$97,432.48	3,951	\$984.17	\$24.66
19027	ENBREL SURECLICK	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	19	3	\$95,004.01	532	\$5,000.21	\$178.58
19027	LATUDA	*ANTIPSYCHOTICS/ANTIMANIC AGENTS*	B	2	N	53	9	\$94,237.93	1,650	\$1,778.07	\$57.11
19027	JANUVIA	*ANTIDIABETICS*	B	2	N	126	33	\$84,653.14	6,000	\$671.85	\$14.11
19027	CIALIS	*CARDIOVASCULAR AGENTS - MISC.*	B	2	N	122	39	\$73,243.58	5,656	\$600.36	\$12.95
19027	NOXAFIL	*ANTIFUNGALS*	B	2	N	9	1	\$71,901.45	270	\$7,989.05	\$266.30
19027	FARXIGA	*ANTIDIABETICS*	B	2	N	121	24	\$70,202.33	4,590	\$580.18	\$15.29
19027	LANTUS SOLOSTAR	*ANTIDIABETICS*	B	2	N	126	28	\$68,429.08	5,327	\$543.09	\$12.85
19027	XELJANZ XR	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	16	3	\$67,437.25	480	\$4,214.83	\$140.49
19027	ELIQUIS	*ANTICOAGULANTS*	B	2	N	93	27	\$65,969.23	4,903	\$709.35	\$13.45
19027	STELARA	*DERMATOLOGICALS*	B	2	Y	3	1	\$64,470.03	270	\$21,490.01	\$238.78
19027	CREON	*DIGESTIVE AIDS*	B	2	N	15	6	\$58,690.69	485	\$3,912.71	\$121.01
19027	HUMALOG	*ANTIDIABETICS*	B	2	N	46	14	\$56,467.29	2,098	\$1,227.55	\$26.91
19027	TRINTELLIX	*ANTIDEPRESSANTS*	B	3	N	122	31	\$55,928.88	4,320	\$458.43	\$12.95
19027	XARELTO	*ANTICOAGULANTS*	B	2	N	95	17	\$50,381.36	3,607	\$530.33	\$13.97
19027	INVOKANA	*ANTIDIABETICS*	B	2	N	72	17	\$50,221.15	3,280	\$697.52	\$15.31
19027	ADVAIR DISKUS	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	91	33	\$49,731.89	3,750	\$546.50	\$13.26
19027	JARDIANCE	*ANTIDIABETICS*	B	2	N	60	23	\$44,886.39	2,940	\$748.11	\$15.27

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Tulare

TOP DRUGS BY CLAIM COUNT

County of Tulare

Based on Paid Date: 1/1/2018 - 9/30/2018

Client ID	Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
19027	ATORVASTATIN CALCIUM	*ANTHYPERLIPEMICS*	G	1	N	956	273	\$27,439.84	53,733	\$28.70	\$0.51
19027	LEVOTHYROXINE SODIUM	*THYROID AGENTS*	G	1	N	950	245	\$22,711.58	52,636	\$23.91	\$0.43
19027	HYDROCODONE/ACETAMINOPHEN	*ANALGESICS - OPIOID*	G	1	N	897	336	\$34,115.11	18,289	\$38.03	\$1.87
19027	LISINAPRIL	*ANTHYPERTENSIVES*	G	1	N	876	254	\$5,636.68	49,476	\$6.43	\$0.11
19027	METFORMIN HCL	*ANTIDIABETICS*	G	1	N	605	191	\$9,965.10	31,696	\$16.47	\$0.31
19027	OMEPRAZOLE	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	593	196	\$11,271.04	30,342	\$19.01	\$0.37
19027	AMLODIPINE BESYLATE	*CALCIUM CHANNEL BLOCKERS*	G	1	N	542	162	\$3,129.19	29,485	\$5.77	\$0.11
19027	SERTRALINE HCL	*ANTIDEPRESSANTS*	G	1	N	510	147	\$5,824.90	23,121	\$11.42	\$0.25
19027	ALPRAZOLAM	*ANTIANKXIETY AGENTS*	G	1	N	493	155	\$2,457.24	13,259	\$4.98	\$0.19
19027	AZITHROMYCIN	*MACROLIDES*	G	1	N	475	398	\$7,769.14	2,807	\$16.36	\$2.77
19027	MONTELUKAST SODIUM	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	G	1	N	458	151	\$10,938.96	19,680	\$23.88	\$0.56
19027	GABAPENTIN	*ANTICONVULSANTS*	G	1	N	454	150	\$12,136.12	17,001	\$26.73	\$0.71
19027	LOSARTAN POTASSIUM	*ANTHYPERTENSIVES*	G	1	N	443	124	\$6,836.95	22,978	\$15.43	\$0.30
19027	METOPROLOL SUCCINATE ER	*BETA BLOCKERS*	G	1	N	408	126	\$22,683.41	23,380	\$55.60	\$0.97
19027	AMOXICILLIN	*PENICILLINS*	G	1	N	408	326	\$2,955.28	3,446	\$7.24	\$0.86
19027	HYDROCHLOROTHIAZIDE	*DIURETICS*	G	1	N	385	123	\$3,061.33	20,556	\$7.95	\$0.15
19027	PANTOPRAZOLE SODIUM	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	374	122	\$6,726.53	19,470	\$17.99	\$0.35
19027	AMOXICILLIN/CLAVULANATE P	*PENICILLINS*	G	1	N	350	298	\$14,858.24	3,570	\$42.45	\$4.16
19027	PREDNISONE	*CORTICOSTEROIDS*	G	1	N	310	208	\$2,387.25	5,723	\$7.70	\$0.42
19027	FLUTICASONE PROPIONATE	*NASAL AGENTS - SYSTEMIC AND TOPICAL*	G	1	N	308	198	\$6,685.60	11,905	\$21.71	\$0.56
19027	TRAMADOL HCL	*ANALGESICS - OPIOID*	G	1	N	296	130	\$1,591.40	5,302	\$5.38	\$0.30
19027	VITAMIN D	*VITAMINS*	G	1	N	292	116	\$1,811.55	13,156	\$6.20	\$0.14
19027	BUPROPION HCL XL	*ANTIDEPRESSANTS*	G	1	N	285	86	\$25,772.33	13,740	\$90.43	\$1.88
19027	ROSUVASTATIN CALCIUM	*ANTHYPERLIPEMICS*	G	1	N	276	78	\$16,062.54	14,956	\$58.20	\$1.07
19027	ESCITALOPRAM OXALATE	*ANTIDEPRESSANTS*	G	1	N	263	86	\$4,664.20	11,850	\$17.73	\$0.39

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Fresno

TOP DRUGS BY INGREDIENT COST

County of Fresno

Based on Paid Date: 1/1/2018 - 9/30/2018

Client ID	Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
19028	HUMIRA PEN	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	52	11	\$312,726.22	1,456	\$6,013.97	\$214.78
19028	LATUDA	*ANTI-PSYCHOTICS/ANTIMANIC AGENTS*	B	2	N	130	32	\$229,964.73	4,980	\$1,768.96	\$46.18
19028	ENBREL SURECLICK	*ANALGESICS - ANTI-INFLAMMATORY*	B	2	Y	40	8	\$207,781.04	1,120	\$5,194.53	\$185.52
19028	TRULICITY	*ANTI-DIABETICS*	B	2	N	173	45	\$166,418.05	6,554	\$961.95	\$25.39
19028	JANUVIA	*ANTI-DIABETICS*	B	2	N	185	53	\$134,883.91	9,600	\$729.10	\$14.05
19028	REVLIMID	*MISCELLANEOUS THERAPEUTIC CLASSES*	B	2	Y	9	1	\$132,872.46	252	\$14,763.61	\$527.27
19028	CIALIS	*CARDIOVASCULAR AGENTS - MISC.*	B	2	N	201	72	\$128,126.95	9,857	\$637.45	\$13.00
19028	VICTOZA	*ANTI-DIABETICS*	B	2	N	120	28	\$126,542.95	5,324	\$1,054.52	\$23.77
19028	HUMALOG KWIKPEN	*ANTI-DIABETICS*	B	2	N	111	32	\$126,271.07	4,844	\$1,137.58	\$26.07
19028	LANTUS SOLOSTAR	*ANTI-DIABETICS*	B	2	N	160	56	\$117,418.90	8,913	\$733.87	\$13.17
19028	SPRYCEL	*ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES*	B	2	Y	9	1	\$115,743.78	270	\$12,860.42	\$428.68
19028	HUMALOG	*ANTI-DIABETICS*	B	2	N	79	21	\$105,204.57	3,400	\$1,331.70	\$30.94
19028	FARXIGA	*ANTI-DIABETICS*	B	2	N	112	32	\$98,094.49	6,540	\$875.84	\$15.00
19028	METFORMIN HCL ER	*ANTI-DIABETICS*	G	1	N	213	86	\$92,120.20	13,502	\$432.49	\$6.82
19028	NOVOLOG FLEXPEN	*ANTI-DIABETICS*	B	2	N	81	26	\$86,813.87	3,869	\$1,071.78	\$22.44
19028	ESBRIET	*RESPIRATORY AGENTS - MISC.*	B	2	Y	9	1	\$84,833.25	270	\$9,425.92	\$314.20
19028	VYVANSE	*ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS*	B	2	N	254	55	\$83,113.45	8,300	\$327.22	\$10.01
19028	SYMBICORT	*ANTI-ASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	213	107	\$79,468.81	7,688	\$373.09	\$10.34
19028	INVOKANA	*ANTI-DIABETICS*	B	2	N	91	27	\$79,064.12	5,220	\$868.84	\$15.15
19028	LETAIRIS	*CARDIOVASCULAR AGENTS - MISC.*	B	2	Y	8	1	\$77,294.48	240	\$9,661.81	\$322.06
19028	TECFIDERA	*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.*	B	2	Y	10	1	\$76,896.30	300	\$7,689.63	\$256.32
19028	ADVAIR DISKUS	*ANTI-ASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	136	45	\$76,232.58	5,820	\$560.53	\$13.10
19028	SIMPONI	*ANALGESICS - ANTI-INFLAMMATORY*	B	3	Y	16	2	\$72,026.88	480	\$4,501.68	\$150.06
19028	LYRICA	*ANTI-CONVULSANTS*	B	2	N	104	29	\$65,557.10	3,695	\$630.36	\$17.74
19028	JARDIANCE	*ANTI-DIABETICS*	B	2	N	67	29	\$65,403.14	4,350	\$976.17	\$15.04

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Fresno

TOP DRUGS BY CLAIM COUNT

County of Fresno

Based on Paid Date: 1/1/2018 - 9/30/2018

Client ID	Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
19028	HYDROCODONE/ACETAMINOPHEN	*ANALGESICS - OPIOID*	G	1	N	1,292	534	\$49,533.16	23,657	\$38.34	\$2.09
19028	LEVOTHYROXINE SODIUM	*THYROID AGENTS*	G	1	N	1,246	359	\$34,401.81	76,948	\$27.61	\$0.45
19028	LISINAPRIL	*ANTIHYPERTENSIVES*	G	1	N	1,233	414	\$9,440.76	79,927	\$7.66	\$0.12
19028	ATORVASTATIN CALCIUM	*ANTIHYPERTENSIVES*	G	1	N	1,225	455	\$43,854.88	84,198	\$35.80	\$0.52
19028	METFORMIN HCL	*ANTIDIABETICS*	G	1	N	947	315	\$17,528.68	54,207	\$18.51	\$0.32
19028	GABAPENTIN	*ANTICONVULSANTS*	G	1	N	783	237	\$20,167.91	30,506	\$25.76	\$0.66
19028	AMLODIPINE BESYLATE	*CALCIUM CHANNEL BLOCKERS*	G	1	N	694	219	\$4,666.97	44,250	\$6.72	\$0.11
19028	FLUTICASONE PROPIONATE	*NASAL AGENTS - SYSTEMIC AND TOPICAL*	G	1	N	662	426	\$14,608.36	26,210	\$22.07	\$0.56
19028	OMEPRAZOLE	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	636	289	\$13,682.58	36,774	\$21.51	\$0.37
19028	AZITHROMYCIN	*MACROLIDES*	G	1	N	635	574	\$11,020.47	3,560	\$17.36	\$3.10
19028	AMOXICILLIN	*PENICILLINS*	G	1	N	588	543	\$4,742.97	5,260	\$8.07	\$0.90
19028	SERTRALINE HCL	*ANTIDEPRESSANTS*	G	1	N	575	179	\$8,050.30	29,108	\$14.00	\$0.28
19028	PROAIR HFA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	553	371	\$36,512.98	13,212	\$66.03	\$2.76
19028	AMOXICILLIN/CLAVULANATE P	*PENICILLINS*	G	1	N	530	471	\$22,896.12	5,466	\$43.20	\$4.19
19028	IBU	*ANALGESICS - ANTI-INFLAMMATORY*	G	1	N	518	395	\$6,474.39	11,849	\$12.50	\$0.55
19028	ALPRAZOLAM	*ANTIAXIETY AGENTS*	G	1	N	494	165	\$2,101.12	12,756	\$4.25	\$0.16
19028	VENTOLIN HFA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	487	375	\$26,654.75	10,601	\$54.73	\$2.51
19028	BUPROPION HCL XL	*ANTIDEPRESSANTS*	G	1	N	484	140	\$46,282.06	23,065	\$95.62	\$2.01
19028	LOSARTAN POTASSIUM	*ANTIHYPERTENSIVES*	G	1	N	464	172	\$10,186.41	30,660	\$21.95	\$0.33
19028	PREDNISONE	*CORTICOSTEROIDS*	G	1	N	464	334	\$2,759.35	6,142	\$5.95	\$0.45
19028	METOPROLOL SUCCINATE ER	*BETA BLOCKERS*	G	1	N	461	144	\$30,399.32	29,740	\$65.94	\$1.02
19028	MONTELUKAST SODIUM	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	G	1	N	444	166	\$12,971.37	22,315	\$29.21	\$0.58
19028	ESCITALOPRAM OXALATE	*ANTIDEPRESSANTS*	G	1	N	416	129	\$10,604.72	19,573	\$25.49	\$0.54
19028	CYCLOBENZAPRINE HCL	*MUSCULOSKELETAL THERAPY AGENTS*	G	1	N	413	246	\$2,695.19	10,460	\$6.53	\$0.26
19028	IBUPROFEN	*ANALGESICS - ANTI-INFLAMMATORY*	G	1	N	393	335	\$4,179.03	7,738	\$10.63	\$0.54

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Marysville

TOP DRUGS BY INGREDIENT COST

County of Marysville

Based on Paid Date: 1/1/2018 - 9/30/2018

Client ID	Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
19029	HARVONI	*ANTIVIRALS*	B	2	Y	2	1	\$62,748.00	56	\$31,374.00	\$1,120.50
19029	GENVOYA	*ANTIVIRALS*	B	2	Y	5	1	\$15,376.30	150	\$3,075.26	\$102.51
19029	BIKTARVY	*ANTIVIRALS*	B	2	Y	2	1	\$6,150.52	60	\$3,075.26	\$102.51
19029	VESICARE	*URINARY ANTISPASMODICS*	B	2	N	9	1	\$3,191.66	270	\$354.63	\$11.82
19029	ROZEREM	*HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENTS*	B	2	N	7	1	\$2,696.75	210	\$385.25	\$12.84
19029	JULUCA	*ANTIVIRALS*	B	3	Y	1	1	\$2,692.48	30	\$2,692.48	\$89.75
19029	SPIRIVA RESPIMAT	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	2	1	\$2,290.52	180	\$1,145.26	\$12.73
19029	AMNESTEEM	*DERMATOLOGICALS*	G	1	N	2	1	\$2,234.30	60	\$1,117.15	\$37.24
19029	LYRICA	*ANTICONVULSANTS*	B	2	N	9	1	\$2,046.69	270	\$227.41	\$7.58
19029	PULMICORT FLEXHALER	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	3	1	\$1,982.88	270	\$660.96	\$7.34
19029	HYDROCODONE/ACETAMINOPHEN	*ANALGESICS - OPIOID*	G	1	N	23	10	\$1,333.75	427	\$57.99	\$3.12
19029	DULERA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	4	1	\$1,270.32	120	\$317.58	\$10.59
19029	TEGRETOL	*ANTICONVULSANTS*	B	3	N	3	1	\$1,239.18	270	\$413.06	\$4.59
19029	SALSALATE	*ANALGESICS - NonNarcotic*	G	1	N	7	1	\$979.38	330	\$139.91	\$2.97
19029	DAPSONE	*DERMATOLOGICALS*	G	1	N	2	1	\$965.00	60	\$482.50	\$16.08
19029	PREMPRO	*ESTROGENS*	B	2	N	2	1	\$904.99	140	\$452.50	\$6.46
19029	OSELTAMIVIR PHOSPHATE	*ANTIVIRALS*	G	1	N	6	5	\$880.94	38	\$146.82	\$23.18
19029	ESOMEPRAZOLE MAGNESIUM	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	13	2	\$819.10	390	\$63.01	\$2.10
19029	AMPHETAMINE/DEXTRAMPHETA	*ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS*	G	1	N	6	2	\$776.94	180	\$129.49	\$4.32
19029	VIIBRYD	*ANTIDEPRESSANTS*	B	2	N	1	1	\$716.02	90	\$716.02	\$7.96
19029	VENTOLIN HFA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	13	7	\$712.66	296	\$54.82	\$2.41
19029	METHYLPHENIDATE HCL ER	*ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS*	G	1	N	2	1	\$627.98	60	\$313.99	\$10.47
19029	MONTELUKAST SODIUM	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	G	1	N	24	7	\$574.86	900	\$23.95	\$0.64
19029	LEVOTHYROXINE SODIUM	*THYROID AGENTS*	G	1	N	15	5	\$546.25	1,170	\$36.42	\$0.47
19029	SPIRONOLACTONE/HYDROCHLOR	*DIURETICS*	G	1	N	5	2	\$542.65	450	\$108.53	\$1.21

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Marysville

TOP DRUGS BY CLAIM COUNT

County of Marysville

Based on Paid Date: 1/1/2018 - 9/30/2018

Client ID	Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
19029	MONTELUKAST SODIUM	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	G	1	N	24	7	\$574.86	900	\$23.95	\$0.64
19029	HYDROCODONE/ACETAMINOPHEN	*ANALGESICS - OPIOID*	G	1	N	23	10	\$1,333.75	427	\$57.99	\$3.12
19029	OMEPRAZOLE	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	20	5	\$399.32	1,140	\$19.97	\$0.35
19029	SULFAMETHOXAZOLE/TRIMETHO	*ANTI-INFECTIVE AGENTS - MISC.*	G	1	N	17	6	\$200.04	318	\$11.77	\$0.63
19029	LEVOTHYROXINE SODIUM	*THYROID AGENTS*	G	1	N	15	5	\$546.25	1,170	\$36.42	\$0.47
19029	ALLOPURINOL	*GOUT AGENTS*	G	1	N	14	3	\$286.97	510	\$20.50	\$0.56
19029	ATORVASTATIN CALCIUM	*ANTIHYPERTENSIVES*	G	1	N	14	2	\$277.69	540	\$19.84	\$0.51
19029	ESCITALOPRAM OXALATE	*ANTIDEPRESSANTS*	G	1	N	14	2	\$157.82	420	\$11.27	\$0.38
19029	ESOMEPRAZOLE MAGNESIUM	*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*	G	1	N	13	2	\$819.10	390	\$63.01	\$2.10
19029	VENTOLIN HFA	*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*	B	2	N	13	7	\$712.66	296	\$54.82	\$2.41
19029	AMOXICILLIN	*PENICILLINS*	G	1	N	12	11	\$114.10	138	\$9.51	\$0.83
19029	AZITHROMYCIN	*MACROLIDES*	G	1	N	12	9	\$221.51	108	\$18.46	\$2.05
19029	AMOXICILLIN/CLAVULANATE P	*PENICILLINS*	G	1	N	10	10	\$435.93	101	\$43.59	\$4.32
19029	ASPIR-LOW	*ANALGESICS - NonNarcotic*	G	1	N	10	2	\$13.99	480	\$1.40	\$0.03
19029	LOSARTAN POTASSIUM	*ANTIHYPERTENSIVES*	G	1	N	10	2	\$110.36	360	\$11.04	\$0.31
19029	DULOXETINE HCL	*ANTIDEPRESSANTS*	G	1	N	9	1	\$329.67	270	\$36.63	\$1.22
19029	LYRICA	*ANTICONVULSANTS*	B	2	N	9	1	\$2,046.69	270	\$227.41	\$7.58
19029	METFORMIN HCL	*ANTIDIABETICS*	G	1	N	9	2	\$175.66	510	\$19.52	\$0.34
19029	VESICARE	*URINARY ANTISPASMODICS*	B	2	N	9	1	\$3,191.66	270	\$354.63	\$11.82
19029	ALPRAZOLAM	*ANTI ANXIETY AGENTS*	G	1	N	8	2	\$12.26	80	\$1.53	\$0.15
19029	TRIAMCINOLONE ACETONIDE	*DERMATOLOGICALS*	G	1	N	8	6	\$83.62	120	\$10.45	\$0.70
19029	VENLAFAXINE HCL ER	*ANTIDEPRESSANTS*	G	1	N	8	1	\$155.89	270	\$19.49	\$0.58
19029	ZOLPIDEM TARTRATE	*HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENTS*	G	1	N	8	1	\$24.80	240	\$3.10	\$0.10
19029	GLIPIZIDE ER	*ANTIDIABETICS*	G	1	N	7	1	\$270.55	210	\$38.65	\$1.29
19029	PREDNISONE	*CORTICOSTEROIDS*	G	1	N	7	6	\$27.36	57	\$3.91	\$0.48